In the study, participants taking AMX0035 had a statistically significant slowing of ALS disease progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) compared to placebo (p<0.05),
The latest approval means that XTANDI is indicated for the treatment of three distinct forms of advanced prostate cancer that include non-metastatic and metastatic castration-resistant prostate cancer (CRPC),
Under the terms of the agreement, AstraZeneca has received a payment of $178m from Cheplapharm. The Company may also receive future sales-contingent payments of up to $61m. The
The two phase 3 trials for Jardiance called EMPERIAL-Reduced and EMPERIAL-Preserved were carried out in adults with chronic heart failure with reduced and preserved ejection fraction, respectively. In
The study showed adding Tecentriq (atezolizumab) to Cotellic (cobimetinib) and Zelboraf (vemurafenib) helped to reduce the risk of disease worsening or death, compared to placebo plus Cotellic and
These new data, from a primary analysis of the FeDeriCa study, will be presented in a spotlight session at 07.00 CST today at the 2019 San Antonio Breast
It is estimated that about 8 percent of patients with DMD have this mutation. “The FDA recognizes the urgent need for new medical treatments for serious neurological disorders
According to 3M, the total consideration includes cash, an interest-bearing security, and a 17% non-controlling stake in the new company that will hold the divested drug delivery business.
According to the US biopharma company, lebrikizumab is a monoclonal antibody that can bind with very high affinity with the Interleukin 13 (IL-13) cykotine. Through this mechanism, the
Vedanta also announced the formation of its Immuno-Oncology Scientific Advisory Board (SAB), which is comprised of experts in immunology, immuno-oncology and the microbiome, to support the planned clinical
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.